In a large population-based US health care cohort with exome sequencing data, we found that individuals with P/LP variants in TTR identified by genomic screening had significantly increased odds of heart disease (including heart failure, cardiomyopathy, and atrial fibrillation) on or after the age of 60 years. This evidence concerns the gene TTR and heart failure.